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Abstract: Each year approximately 2400 pregnancies 
develop folic acid-preventable spina bifida and anenceph-
aly in Europe. Currently, 70% of all affected pregnancies 
are terminated after prenatal diagnosis. The prevalence of 
neural tube defects (NTDs) has been significantly lowered 
in more than 70 countries worldwide by applying fortifi-
cation with folic acid. Periconceptional supplementation 
of folic acid also reduces the risk of congenital heart dis-
eases, preterm birth, low birth weight, and health prob-
lems associated with child mortality and morbidity. All 
European governments failed to issue folic acid fortifica-
tion of centrally processed and widely eaten foods in order 
to prevent NTDs and other unwanted birth outcomes. The 
estimated average dietary intake of folate in Germany is 
200 μg dietary folate equivalents (DFE)/day. More than 
half of German women of reproductive age do not con-
sume sufficient dietary folate to achieve optimal serum or 
red blood cell folate concentrations ( > 18 or 1000 nmol/L, 
respectively) necessary to prevent spina bifida and anen-
cephaly. To date, targeted supplementation is recom-
mended in Europe, but this approach failed to reduce the 
rate of NTDs during the last 10 years. Public health centers 
for prenatal care and fortification with folic acid in Europe 
are urgently needed. Only such an action will sufficiently 
improve folate status, prevent at least 50% of the NTD 
cases, reduce child mortality and morbidity, and alleviate 
other health problems associated with low folate such as 
anemia.
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Background
Folates have a central role in prevention of birth defects 
and other diseases. Folate deficiency without anemia 
occurs in a large number of individuals [1]. An estimated 
4800 pregnancies are affected by neural tube defects 
(NTDs) each year in Europe [2]. Between 700 and 1000 of 
these cases are yearly diagnosed in Germany and at least 
50% of these birth defects could be prevented by suffi-
cient periconceptional supplementation of folic acid (FA) 
[3]. This article aims at reviewing recent evidence on the 
role of folate mainly during pregnancy and discussing 
strategies for improving folate intake and status. Efforts to 
increase folate intake through natural folate-rich foods are 
unlikely to be effective for health prevention on a popula-
tion basis and would leave a large portion of the popula-
tion, particularly women of reproductive age, at increased 
risk for diseases related to folate insufficiency.
The term dietary folate equivalent (DFE) has been 
introduced which refers to 1 μg natural folate or 0.5 μg of 
FA. The recommended dietary allowance (RDA) for folate 
in German population is 300 μg DFE/day [4] (Table 1), 
whereas the Institute of Medicine (IOM) of the US National 
Academy of Sciences set the RDA for folate to 400 μg DFE 
[5]. Different intake data from the national survey on 
German population (NVSII 2012) showed a mean folate 
intake of 200 μg DFE/day [6]. The median intake of dietary 
folate in young women (19–35 years) is from 170 to 181 μg 
DFE/day, thus clearly showing that the majority of them 
are at risk for insufficient intake of folate [6]. To recom-
mend doubling the folate intake from dietary sources [4] 
(increase by ∼200 μg DFE/day) in the population appears 
unrealistic. In fact, the German nutrition survey NVSII 
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showed that healthy lifestyle patterns did not predict a 
difference in dietary folate intake of more than 30 μg DFE/
day [6]. In contrast, only people using vitamin supple-
ments with FA were able to obtain a median total folate 
intake of 500 μg DFE/day [6].
Pteroylglutamic acid [folic acid (FA)] is the synthetic 
form of folate that is used in supplements and fortifica-
tion of foods. FA is not biologically active unless reduced 
to tetrahydrofolate and then converted to methylfolate. 
FA from supplements or fortified foods is easily absorbed 
and converted to the active forms that increase serum 
folate and prevent anemia, hyperhomocysteinemia, and 
birth defects. FA increases serum and red blood cell (RBC)-
folate in a dose-, time-, and baseline-dependent manner 
[1]. The serum concentration of folate mirrors recent 
folate status, RBC-folate concentration is a long-term 
marker that reflects folate storage, and total homocyst-
eine (tHcy) represents a surrogate functional markers for 
folate status [7]. Serum folate is preferred over RBC-folate 
because it can be reliably measured using immunologi-
cal or chromatography methods, shows faster response 
after supplementation, and reflects the amount available 
for transfer via the placenta. Polymorphisms in the folate 
cycle [i.e., methylenetetrahydrofolate reductase (MTHFR)] 
interfere with folate status, requirements, and diseases 
susceptibility. Because screening for the  polymorphism 
on a population level is not recommended, the RDA for 
folate should be adequate to cover the requirements of 
the most liable genotype (i.e. MTHFR677 TT). A signifi-
cant association between NTDs and the MTHFR677 TT 
genotype has been reported [8]. Irrespective of the geno-
type, a serum folate concentration of at least 18 nmol/L 
(or RBC-folate > 1000 nmol/L) is necessary to prevent 
most cases of folate-responsive birth defects. This level 
must be reached before conception. However, unless 
women use supplementary FA doses ranging from 400 
to 800 μg/day, sufficient folate levels cannot be achieved 
within 1 month in the majority of women who start from 
low or intermediate baseline folate (discussed in [9]).
Timely supplementation of folate 
prevents birth defects
NTDs such as spina bifida and anencephaly are structural 
malformations of the central nervous system caused by 
delayed closure of the neural tube in the first few weeks 
after conception [10]. NTD births constitute considerable 
social and economic burden for the affected families and 
the health system [11]. The lifetime hospital admissions 
because of secondary conditions is markedly higher in 
patients with spina bifida compared to healthy individu-
als [12]. The relative risk (RR) of death among children 
with spina bifida is higher compared to children without 
birth defects [13]. The higher rate of premature death in 
adults [14] causes loss of working years and healthy life 
years. The disease is associated not only with early mortal-
ity [14], but also with greater need for health care services, 
in particular during the first years of life. In general, chil-
dren aged from 1 to 17 years had 13 times higher medical 
expenditures than non-spina bifida children [15].
At least 50% of these birth defects can be prevented 
by improving maternal folate status before conception 
[3, 16–19]. The prevention potential of NTDs by provid-
ing FA depends on the women’s baseline folate status 
markers. A dose-response relationship is observed 
between the risk and maternal serum or RBC-folate 
even within the reference range [20]. Protective levels 
of serum and RBC-folate are estimated to be  > 18 nmol/L 
and  > 1000 nmol/L respectively [9, 20, 21]. After introduc-
ing a population-wide fortification of staple foods with 
FA, the prevalence of NTDs in the US, Costa Rica [22], and 
many other countries declined to  < 5–6 cases per 10,000 
births and thus, it is now only about half as high as the 
average rate of 9.3 cases per 10,000 births in Europe in 
2012 (source EUROCAT, University of Ulster). The patho-
genesis of NTDs and the protective mechanisms of FA 
are still not well understood [23], but it appears that FA 
cannot prevent all NTD cases.
Table 1: Folate intake recommendations (μg/day) and suppplementation recommendations.
Organization   EFSA   D-A-CH   NNR   WHO   IOM
Year   2014   2013   2012   2004   1998
For adults   330   300   300   400   400
Women of reproductive age   As for adults   As for adults   400   As for adults   As for adults
Pregnant women   600 μg DFE/day   550 μg DFE/day  500 μg DFE/day   600 μg DFE/day  600 μg DFE/day
Women planning 
pregnancy
  No recommendations 
to supplement FA
  Additional FA: 
400 μg/day
  No recommendations 
to supplement
  Additional FA: 
400 μg/day
  Additional FA: 
400 μg/day
NNR = Nordic Nutrition Recommendations, EFSA = European Food Safety Authority, D-A-CH = Deutschland-Austria-Confoederatio Helvetica, 
WHO = World Health Organization, IOM = US Institute of Medicine of the National Academy of Sciences.
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Lower risks for congenital heart defects (CHDs) [24, 
25] were also related to improving maternal folate status 
starting from the periconceptional period, although 
the evidence is not as strong as for the NTDs. However, 
because CHDs are more prevalent [26], the significance of 
preventing CHD is expected to be even higher than that for 
NTDs. Approximately, one in four major cardiac defects 
are predicted to be prevented by timely multivitamin use 
[24]. For example, a Dutch EUROCAT register-based study 
has shown that periconceptional use of FA is associated 
with approximately 20% reduced CHD risk in the infants 
[27]. The results were confirmed by a recent Chinese study 
that showed that the use of FA-containing supplements 
for  ≥ 3 months before pregnancy is associated with approx-
imately 70% reduction in CHD risk (OR = 0.31, 95% CI 0.18–
0.54) [28]. Ionescu-Ittu et al. showed that the risk of severe 
CHD (tetralogy of Fallot, endocardial cushion defects, 
univentricular hearts, truncus arteriosus, or transposition 
complexes) in Quebec administrative databases declined 
by approximately 6% in the years following FA fortifica-
tion in 1998 in Canada (i.e., analyzing birth data between 
1990 and 2005) [29]. In contrast, a recent study in Alberta 
showed that only the prevalence of cases with left ventric-
ular outflow tract obstruction declined after fortification 
when comparing birth data between 1995 and 1997 and 
between 1999 and 2002 [30]. A further case-control study 
on fetuses and infants with conotruncal or limb defects in 
a Californian birth cohort from 1987 to 1988 showed that 
consuming FA-containing supplements reduces the risk 
for conotruncal heart defects [odds ratio 0.53 (0.34–0.85)] 
[31]. However, when looking at soluble folate markers in 
maternal blood, no association was observed between one 
carbon metabolites or B-vitamins in mid-pregnancy and 
the risk of having a child with conotruncal heart defects in 
a population sample from California (2002–2007) [32]. The 
lack of association may be due to the fact that the study 
was conducted after the start of FA fortification in the US 
in 1998. In general, the extent of the CHD risk reduction 
varied, was related to the lesion, and was absent in some 
studies [32].
Birth weight shows a positive association with FA 
intake or folate status [33–35] which is explained by 
extension of the gestational age or prevention of preterm 
birth. Newborns of Dutch women with serum folate  > 25.8 
nmol/L were on average 167 g heavier than those of 
women with serum folate  < 9.3 nmol/L [36]. Considering 
FA supplementation, birth outcomes were studied in new-
borns of Hungarian women. Mean gestational age was 0.3 
week longer and mean birth weight was by 37 g higher 
in women taking FA alone (relatively high dose 5.6 mg/
day) than in the group without any supplementation [33]. 
The rate of preterm births was significantly lower in the 
FA group compared with the reference sample (without 
vitamin supplement) [7.6% vs. 11.8%: OR (95% CI) = 0.68 
(0.63–0.73)], but the rate of low-birth-weight newborns 
was not different [OR (95% CI) = 0.88 (0.62–1.14)] [33]. The 
longest gestational age and lowest rate of preterm birth 
was found after FA supplementation during 2nd to 3rd tri-
mesters (39.9 weeks and 3.8%) and during the entire preg-
nancy, that is, 1st to 3rd trimesters (39.8 weeks and 4.9%), 
followed by the 3rd trimester alone (39.5 weeks and 7.6%) 
[33]. Likewise, the risk for spontaneous preterm birth was 
lowered by approximately 50% in one large Chinese study 
using lower doses of FA (that is, 400 μg/day) starting 
periconceptionally [37]. An elevated plasma tHcy, a folate 
status marker, has been related to a 25% higher risk in the 
offspring to be small for gestational age [38]. Hogeveen 
et al. estimated that a 1.9-μmol/L increase in maternal tHcy 
would result in a decrease in birth weight of 31 g (95% CI: 
–13, –51 g) [38]. A significant public health benefit would 
be expected from reducing the rate of preterm births and 
births with low birth weight.
In addition to poor birth outcome, folate deficiency 
and hyperhomocysteinemia have been related to mater-
nal health, particularly the risk for preeclampsia. FA 
supplementation showed no consistent protective effect 
against preeclampsia [39, 40]. Adequate folate supply 
is also important during lactation. The concentrations 
of folate (the main form is 5-methyltetrahydrofolate) in 
human milk are maintained at levels between 100 and 193 
nmol/L even at low maternal serum folate concentrations 
[41, 42]. Maternal FA supplementation (400 μg/day) after 
birth increased maternal serum folate (10.9–39.0 nmol/L) 
and milk folate levels (from a median of 103 nmol/L to 155 
nmol/L) postpartum [41]. Maternal serum concentrations 
of folate was not a determinant of milk folate [41], suggest-
ing that folate is actively transported into the milk. None-
theless, FA supplementation during lactation is important 
for preserving maternal folate stores, in particular with 
regard to subsequent conceptions.
Folate and postnatal health
Adequate maternal folate status before and during preg-
nancy has been related to better child development [43]. 
Some studies reported a positive effect of maternal folate 
on social competence [44], reduced likelihood to develop 
behavioral problems at 18 month [45], better cognitive 
ability [43], and less risk of hyperactivity and peer prob-
lems in childhood [46]. An association between low 
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maternal serum folate at early pregnancy (  ≤  11 nmol/L) 
and emotional problems of the child at 3  years [OR 
95%CI = 1.70 (1.28–2.25)] was observed in a study on Dutch 
women [47].
Cerebral folate deficiency was observed in a signifi-
cant number of patients with autistic spectrum disorders 
[48]. A recent case-control study on 429 children with 
autism and 278 controls reported that maternal prenatal 
intake of FA  ≥ 600 μg/day (vs.  < 600 μg/day) was associ-
ated with a lower probability of autism in the offspring 
[49]. The association was more impressive in mothers 
with the MTHFR677 TT genotype [49], in accordance with 
an earlier study showing an increased risk for autism in 
the offspring of MTHFR677 TT mothers who were not sup-
plemented with FA prenatally [50]. The Norwegian Mother 
and Child Cohort (MoBa) study, a prospective study on 
85,176 children born between 2002 and 2008 in Norway 
[51], showed that autistic disorders were found in 0.10% 
of children whose mothers took FA (starting before con-
ception and lasting at least up to the 8th gestational week) 
but in 0.21% of those unexposed [adjusted OR 0.61 (95%CI 
0.41–0.90] [51]. Potential negative impact of low maternal 
whole blood folate on behavioral disorders in the children 
has been reported [46]. Emotional problems in the child 
at the age of 3 years were related to maternal folate defi-
ciency during early pregnancy [OR 1.57 (95% CI 1.03–2.38, 
P = 0.03] in the Generation R study [47]. Thus, several lines 
of evidence suggest that improving maternal folate before 
and early in pregnancy is protective against disorders of 
psychological development.
Studies showing high asthma risk in children born 
to mothers supplemented with FA had severe limitations 
in design because they were either not based on accurate 
measurements of folate intake or serum folate, lacked 
a validated definition of asthma, and did not consider 
child age or relevant environmental factors [52]. Hungar-
ian children born to women supplemented with multivi-
tamin-containing FA or trace elements without FA were 
examined between postnatal months 8 and 12 [53]. There 
was no difference in the occurrence of serious or chronic 
diseases except for atopic dermatitis, asthma, and wheezy 
bronchitis which were more frequent in the infants of 
multivitamin-supplemented mothers [53]. In a long-term 
follow-up study on 6-year-old children of the same Hun-
garian trial, 147 children born to mothers with FA-con-
taining multivitamin supplementation and 142 children 
who had mothers with trace element supplementation 
only were re-examined [54]. There were no differences in 
the rate and distribution of disorders including allergies 
or any other adverse effect [54]. Therefore, the previously 
found association of atopic dermatitis, asthma, or wheezy 
bronchitis with maternal multivitamin supplementation 
during gestation was not confirmed [54].
Folate, aging, and population-
attributable risk of diseases
An intriguing issue is whether tHcy is a marker for B-vita-
min deficiency or a causal risk factor for age-related disor-
ders. Hyperhomocysteinemia is associated with coronary 
heart disease (CVD) and stroke in case-control studies. A 
meta-analysis estimated that lowering tHcy by 25% may 
reduce the risk of coronary heart disease by 11% and 
that of stroke by 19% [55]. However, analyzing data on 
the association of tHcy with the MTHFR C677T polymor-
phism from published and unpublished datasets did not 
confirm a significant effect of tHcy on CVD [56]. Lowering 
tHcy failed to reduce cardiovascular events or mortality, 
but lowered stroke risk [57] which is in line with a moder-
ate reduction of stroke incidence after FA fortification in 
North America in 1998 [58].
Elevated concentrations of plasma tHcy predicted the 
risk of future dementia in longitudinal studies [59]. Brain 
neuroimaging revealed an association between elevated 
tHcy and lower subcortical brain volumes and cortical 
thickness, volume, and surface area in elderly people 
[60]. Vitamin B treatment has been shown to slow brain 
volume shrinkage [61], prevent atrophy of gray matter [62], 
and slow cognitive decline in people with mild cognitive 
impairment [63], an effect that was not confirmed by all 
studies [64]. The effect of Hcy-lowering was confined to 
participants with baseline tHcy  > 11.0 μmol/L.
The risk of osteoporosis, hip fractures, bone mineral 
density [65, 66], or age-related macular degeneration 
has been also related to hyperhomocysteinemia, but the 
response to tHcy was not conclusive. Therefore, consider-
ing the current evidence, we conclude that tHcy lowering 
will not reduce secondary CVD or already manifested cog-
nitive dysfunction but is likely to reduce the risk of stroke.
Folic acid fortification has been shown to be safe for 
the entire population. Large trials of FA supplementa-
tion with doses up to 10 times higher than the average 
intake confirms that such a policy is safe [18, 56, 67, 68]. 
Reports on increased colon cancer risk that appeared in 
1996 almost simultaneously with the approval of food for-
tification by the FDA [69] were not confirmed later [70] or 
even by controlled trials using FA supplementation [68, 
71–73]. Considering results from controlled trials and data 
from countries applying fortification programs since 1998, 
there is no evidence that cancer risk can be attributed to or 
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altered by (i.e., increased or decreased) low or moderate 
intake of FA.
Improving population folate status
Currently, there is no consensus on folate intake recom-
mendations for the population in several parts of the world. 
Although, there is a firm evidence that periconceptional 
supplementation is crucial, the recommendations vary even 
for women of reproductive age or those planning for preg-
nancy (Table 1). Fortification strategies provide approxi-
mately 150 μg/day FA, an amount which is lower than all 
current RDAs. This amount is thought to achieve optimal 
folate markers for preventing NTDs. The traditional “refer-
ence range” for serum folate was based on experiments con-
ducted by Victor Herbert who induced experimental folate 
depletion and defined the cut-off for serum folate where 
anemia becomes expressed [74]. However, recent evidence 
suggests that anemia may be a late manifestation of severe 
folate deficiency [75] and NTD prevention by FA occur in 
women without frank anemia or folate deficiency [21].
One strategy to improve maternal folate status is 
targeted supplementation of young women. In spite of 
strategies targeting the public as well as health care 
professionals, the recommendation to supplement FA 
periconceptionally was not successful in 60–70% of the 
women [76] because of the short-time interval available 
for NTD prevention. The importance of periconceptional 
services as an obligatory medical infrastructure of effec-
tive FA/multivitamin supplementation is supported by the 
Hungarian experience [77]. Periconceptional services are 
not offered by the current European health care structure. 
In Germany and in other parts of Europe, supplementa-
tion recommendations failed to enhance vitamin use and 
to reduce the incidence of NTDs during the last 10 years 
[78]. Therefore, integrating antenatal centers within the 
health care system, which can provide personalized care 
for all young women, is urgently needed in countries not 
applying mandatory fortification.
The most important factors associated with mater-
nal folate deficiency or lack of supplementation before 
pregnancy were young age, low education, low income, 
smoking before pregnancy, obesity, and immigration 
background. Educational programs showed a significant 
increase in the awareness of women; however, the effect 
on supplement usage was insufficient [79]. The use of 
FA supplements is highly dependent on the educational 
and economic status of the individuals. For prepregnancy 
supplementation of FA to be effective, long-term and 
repeated educational and monitoring programs must be 
implemented. Obviously, engagement of health care pro-
viders and policy makers is required to reach adequate 
preventive measures on a population level.
The mandatory fortification of staple foods with FA is 
an alternative strategy that has been practiced in the US 
and Canada since 1998 and meanwhile has been imple-
mented in over 70 countries with the aim of increasing 
the daily folate intake by approximately 200 μg DFE. The 
fortification has shown to be effective in terms of low-
ering tHcy, increasing serum, and RBC-folate [80, 81], 
eliminating anemia [82], and reducing NTD [22]. Fortifi-
cation of staple foods requires supportive legislations or 
regulations, and its implementation and effects should be 
monitored. Compared to targeted supplementation, forti-
fication is far more efficient and cost-effective [83].
Conclusions
The low dietary folate intake in European women explains 
endemic spina bifida and anencephaly. Mandatory forti-
fication of staple foods with FA has proven to be efficient 
and cost-effective in more than 70 countries worldwide, 
but it requires legislation and continuous monitoring. 
Optimal folate status should be defined based on serum 
or RBC folate concentrations. An optimal status cannot 
be achieved on a population level by only recommend-
ing increased intake of natural folates. Targeted supple-
mentation currently recommended in Europe can improve 
folate status. However, this theoretical option has been 
ineffective and failed to reduce NTDs in Europe in the last 
10 years. Although voluntary fortification can offer an 
option, consumer’s health awareness, education, and eco-
nomic status determine its efficacy. There are currently no 
nutritional policies in Europe to monitor the results. Pop-
ulation folate status as a public health issue requires more 
awareness from health care providers and authorities.
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